Get the Stockscreener App
0.2194
7.02%
0.0144
After Hours:
.21
-0.0094
-4.28%
Syros Pharmaceuticals Inc stock is traded at $0.2194, with a volume of 1.12M.
It is up +7.02% in the last 24 hours and up +4.88% over the past month.
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
See More
Previous Close:
$0.205
Open:
$0.2112
24h Volume:
1.12M
Relative Volume:
0.13
Market Cap:
$5.89M
Revenue:
$9.94M
Net Income/Loss:
$-144.49M
P/E Ratio:
-0.0434
EPS:
-5.05
Net Cash Flow:
$-103.90M
1W Performance:
-2.49%
1M Performance:
+4.88%
6M Performance:
-96.64%
1Y Performance:
-96.89%
1-Day Range:
$0.206
$0.23
1-Week Range:
$0.202
$0.2467
52-Week Range:
$0.183
$7.96
Syros Pharmaceuticals Inc Stock (SYRS) Company Profile
Name
Syros Pharmaceuticals Inc
Sector
Industry
Phone
617-744-1340
Address
35 CAMBRIDGE PARK DRIVE, CAMBRIDGE
Compare SYRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SYRS
Syros Pharmaceuticals Inc
|
0.2194 | 5.89M | 9.94M | -144.49M | -103.90M | -5.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Syros Pharmaceuticals Inc Stock (SYRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| Jan-17-20 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-08-19 | Resumed | JMP Securities | Mkt Outperform |
| Feb-14-19 | Resumed | Oppenheimer | Outperform |
| Nov-05-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Mar-13-18 | Reiterated | Wedbush | Outperform |
| Oct-31-17 | Resumed | Piper Jaffray | Overweight |
| Oct-23-17 | Initiated | ROTH Capital | Neutral |
| Aug-10-17 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
View All
Syros Pharmaceuticals Inc Stock (SYRS) Latest News
Syros Pharmaceuticals (NASDAQ:SYRS) Earns Sell Rating from Analysts at StockNews.com - Defense World
Analysts’ Revisions Show Improving Sentiment For Syros Pharmaceuticals Inc (NASDAQ: SYRS) - Stocks Register
Syros Pharmaceuticals (NASDAQ: SYRS) Receives Notice of Listing Non-ComplianceOn January 6, 2025, Syros Pharmaceuticals, Inc. received deficiency letters from the Nasdaq Stock Market, LLC, highlighting certain non-compliance issues with Nasdaq listi - Defense World
Syros Pharmaceuticals faces Nasdaq delisting risk - Investing.com
Syros Pharmaceuticals faces Nasdaq delisting risk By Investing.com - Investing.com South Africa
StockNews.com Initiates Coverage on Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World
Brokerages Set Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Price Target at $3.33 - Defense World
StockNews.com Begins Coverage on Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World
November's phase III successes; Syros, Cassava tumble on misses - BioWorld Online
Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated by Analysts at StockNews.com - Defense World
Syros Pharmaceuticals' SWOT analysis: stock faces challenges after trial setback - Investing.com India
JMP Securities Downgrades Syros Pharmaceuticals (SYRS) - MSN
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc.SYRS - The Eastern Progress Online
Nancy Simonian sells shares in Syros Pharmaceuticals for $10,016 By Investing.com - Investing.com Australia
Nancy Simonian sells shares in Syros Pharmaceuticals for $10,016 - Investing.com
Syros Pharmaceuticals (LTS:0LC7) Enterprise Value : $8.13 Mil (As of Jan. 03, 2025) - GuruFocus.com
Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by StockNews.com - Defense World
SYRS (Syros Pharmaceuticals) 9-Day RSI : 26.16 (As of Nov. 24, 2024) - GuruFocus.com
Syros cut to neutral by H.C. Wainwright on failed drug study - MSN
Syros pharmaceuticals chief development officer sells shares for $7,949 - Investing.com India
Syros pharmaceuticals chief medical officer sells shares for $2,382 By Investing.com - Investing.com Australia
Syros Pharmaceuticals chief legal officer sells $10,320 in stock By Investing.com - Investing.com Australia
Syros Pharmaceuticals chief legal officer sells $10,320 in stock - Investing.com India
Syros Pharmaceuticals CEO Chee Conley sells shares worth $26,932 By Investing.com - Investing.com Canada
Syros pharmaceuticals chief medical officer sells shares for $2,382 - Investing.com
Syros Pharmaceuticals CEO Chee Conley sells shares worth $26,932 - Investing.com
Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q3 2024 Earnings Call Transcript - MSN
Syros downgraded to Market Perform from Outperform at JMP Securities - MSN
Brookline Capital Downgrades Syros Pharmaceuticals (SYRS) - MSN
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal - MSN
Syros Pharmaceuticals hits record low on QIAGEN deal termination and leadership changes - XM
Syros Pharmaceuticals announces major company changes - Investing.com
Syros Pharmaceuticals announces major company changes By Investing.com - Investing.com UK
Syros Pharmaceuticals Faces Financial Struggles Amid Key Challenges - TipRanks
What is HC Wainwright’s Forecast for SYRS Q1 Earnings? - Defense World
Avidity Partners Management LP's Strategic Acquisition in Syros Pharmaceuticals Inc - GuruFocus.com
Blue Owl Capital Holdings LP Increases Stake in Syros Pharmaceuticals Inc - GuruFocus.com
Syros Pharmaceuticals (NASDAQ:SYRS) Earns Neutral Rating from HC Wainwright - Defense World
Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright - Yahoo Finance
JMP Securities cuts Syros Pharma stock rating following unsuccessful trial By Investing.com - Investing.com Australia
Syros Pharmaceuticals' SWOT analysis: stock faces headwinds after trial setback - Investing.com Canada
No RARA, Syros trouble: MDS phase III sinks tamibarotene - BioWorld Online
Syros Pharmaceuticals Inc Stock (SYRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
4.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):